Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 5 th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

Oliver Meyer, Rudolf Schlag, Thomas Stauch, Bastian Fleischmann, Marcel Reiser, Dietrich Kaempfe, Timo Behlendorf, Manfred Welslau, Eyck von der Heyde, Steffen Dörfel, Claudia Willy, Martina Stauch

Blood (2022) 140 (Supplement 1): 2683–2684.

https://doi.org/10.1182/blood-2022-166741

Published: 2022

Journal Articles

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adults Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Mascha Binder, Axel Matzdorff, Falk Nimmerjahn, Mathias Rummel, Oliver Meyer, Tamara Tesanovic, Tanja Sauer

Blood (2021) 138 (Supplement 1): 3151.

https://doi.org/10.1182/blood-2021-147218

Published: 2021

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 4 th Interim Analysis of the German Non-Interventional Trial RISA

Oliver Meyer, Rudolf Schlag, Thomas Stauch, Bastian Fleischmann, Marcel Reiser, Dietrich Kaempfe, Timo Behlendorf, Manfred Welslau, Claudia Willy, Martina Stauch

Blood (2021) 138 (Supplement 1): 3150.

https://doi.org/10.1182/blood-2021-146809

Published: 2021

Journal Articles

From Fatigue Surveys to Survey Fatigue - Notes from Daily Hematology Practice

Axel Matzdorff, MDPhD, Jens U. Rüffer, MD PhD, Oliver Meyer, MD PhD

Blood (2020) 136 (Supplement 1): 39.

https://doi.org/10.1182/blood-2020-134331

Published: 2020

Journal Articles

The New ASH ITP-Guideline Recommendations - Marching Separately, Beating Together

Axel Matzdorff, MDPhD, Oliver Meyer, MD PhD

Blood (2020) 136 (Supplement 1): 11.

https://doi.org/10.1182/blood-2020-134412

Published: 2020

Journal Articles

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adult Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Axel Matzdorff, MDPhD, Mascha Binder, MD, Falk Nimmerjahn, PhD, Oliver Meyer, MD PhD, Mathias J. Rummel, MD PhD, Tamara Tesanovic, PhD, Tanja Sauer

Blood (2020) 136 (Supplement 1): 36–37.

https://doi.org/10.1182/blood-2020-134318

Published: 2020

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3 rd Interim Analysis of the German Non-Interventional Trial RISA

Oliver Meyer, MD PhD, Martina Stauch, Dietrich Kaempfe, MD, Rudolf Schlag, Marcel Reiser, Eyck von der Heyde, Andreas Josting, Margarete Plath, Nadine Ballerstädt, Petra Stark-Lorenzen, Axel Matzdorff, MDPhD

Blood (2020) 136 (Supplement 1): 1–2.

https://doi.org/10.1182/blood-2020-134542

Published: 2020

Journal Articles

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study

Oliver Meyer, James B. Bussel, MD, Raymond S Wong, MBChB, MD, Abderrahim Khelif, Miona Stankovic, Joan Maier, Mansoor N. Saleh

Blood (2018) 132 (Supplement 1): 1152.

https://doi.org/10.1182/blood-2018-99-114694

Published: 2018

Journal Articles

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

Mansoor N. Saleh, James B. Bussel, Gregory Cheng, Oliver Meyer, Christine K. Bailey, Michael Arning, Andres Brainsky

Blood (2013) 121 (3): 537–545.

https://doi.org/10.1182/blood-2012-04-425512

Published: 2013

Includes: Supplemental data

Journal Articles

In Vivo Platelet Production Occurs from an Expanding Pool of Non-Apoptotic Megakaryocytes in a Mouse Model of Passive Immune Thrombocytopenia

Harald Schulze, PhD, Silke Schwiebert, Kathrin Roth, Oliver Meyer, Gabriele Strauss, Anja E Hauser, Imke Meyer

Blood (2012) 120 (21): 1214.

https://doi.org/10.1182/blood.V120.21.1214.1214

Published: 2012

Journal Articles

Platelet Counts Following Eltrombopag Discontinuation in Patients with Chronic Immune Thrombocytopenic Purpura.

Gregory Cheng, Michael Tarantino, MD, Terry Gernsheimer, MD, Oliver Meyer, Andres Brainsky, Nicole L. Stone

Blood (2009) 114 (22): 3517.

https://doi.org/10.1182/blood.V114.22.3517.3517

Published: 2009

Journal Articles

Results of Bone Marrow Examinations in Patients with Chronic Immune Thrombocytopenic Purpura Treated with Eltrombopag.

Mansoor N. Saleh, MD, James B. Bussel, MD, Oliver Meyer, Henrik Frederiksen, Diane Johnni, Manuel Aivado, Andres Brainsky

Blood (2009) 114 (22): 1326.

https://doi.org/10.1182/blood.V114.22.1326.1326

Published: 2009

NARROW

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 5 th Interim Analysis of the Study RISA, with Special Consideration of Treatment Discontinuations

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adults Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 4 th Interim Analysis of the German Non-Interventional Trial RISA

From Fatigue Surveys to Survey Fatigue - Notes from Daily Hematology Practice

The New ASH ITP-Guideline Recommendations - Marching Separately, Beating Together

A Phase II Study to Investigate the Efficacy and Safety of Eltrombopag in Combination with Dexamethasone As First-Line Treatment in Adult Patients with Newly Diagnosed Primary ITP (XPAG-ITP)

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag - Results of the 3 rd Interim Analysis of the German Non-Interventional Trial RISA

Treatment of Immune Thrombocytopenia (ITP) with Eltrombopag (EPAG) in Patients Who Did and Did Not Receive Prior Rituximab (Ritux): A Post-Hoc Analysis of the Extend Study

Safety and efficacy of eltrombopag for treatment of chronic immune thrombocytopenia: results of the long-term, open-label EXTEND study

In Vivo Platelet Production Occurs from an Expanding Pool of Non-Apoptotic Megakaryocytes in a Mouse Model of Passive Immune Thrombocytopenia

Platelet Counts Following Eltrombopag Discontinuation in Patients with Chronic Immune Thrombocytopenic Purpura.

Results of Bone Marrow Examinations in Patients with Chronic Immune Thrombocytopenic Purpura Treated with Eltrombopag.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only